Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype – a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial

References

• DecramerMGOLD: Global strategy for the diagnosis, management, and prevention of COPD2016 [Updated, 2016]. Available from: www.goldcopd.com
   Google Scholar
• HanMKAgustiACalverleyPMChronic obstructive pulmonary disease phenotypes: the future of COPDAm J Respir Crit Care Med2010182559860420522794
   PubMed Web of Science ®Google Scholar
• RabeKFFabbriLMVogelmeierCSeasonal distribution of COPD exacerbations in the prevention of exacerbations with tiotropium in COPD trialChest2013143371171923188489
   PubMed Web of Science ®Google Scholar
• HurstJRDonaldsonGCQuintJKGoldringJJBaghai-RavaryRWedzichaJATemporal clustering of exacerbations in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2009179536937419074596
   PubMed Web of Science ®Google Scholar
• HurstJRVestboJAnzuetoASusceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar
• KimVCrinerGJThe chronic bronchitis phenotype in chronic obstructive pulmonary disease: features and implicationsCurr Opin Pulm Med201521213314125575367
   PubMed Web of Science ®Google Scholar
• RamosFLKrahnkeJSKimVClinical issues of mucus accumulation in COPDInt J Chron Obstruct Pulmon Dis2014913915024493923
   PubMed Web of Science ®Google Scholar
• HoggJCChuFSTanWCSurvival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathologyAm J Respir Crit Care Med2007176545445917556723
   PubMed Web of Science ®Google Scholar
• HoggJCChuFUtokaparchSThe nature of small-airway obstruction in chronic obstructive pulmonary diseaseN Engl J Med2004350262645265315215480
   PubMed Web of Science ®Google Scholar
• VestboJPrescottELangePAssociation of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study GroupAm J Respir Crit Care Med19961535153015358630597
   PubMed Web of Science ®Google Scholar
• PistelliRLangePMillerDDeterminants of prognosis of COPD in the elderly: mucus hypersecretion, infections, cardiovascular comorbidityEur Respir J Suppl20032140 suppl10s14s
   Google Scholar
• BurgelPRNesme-MeyerPChanezPCough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjectsChest2009135497598219017866
   PubMed Web of Science ®Google Scholar
• MartinezFJCalverleyPMGoehringUMBroseMFabbriLMRabeKFEffect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trialLancet2015385997185786625684586
   PubMed Web of Science ®Google Scholar
• MiravitllesMSoler-CataluñaJJCalleMSpanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPDArch Bronconeumol201248724725722561012
   PubMed Web of Science ®Google Scholar
• HanMKTayobNMurraySPredictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapyAm J Respir Crit Care Med2014189121503150824779680
   PubMed Web of Science ®Google Scholar
• VogelmeierCBuhlRCrieeCPGuidelines for the diagnosis and therapy of COPD issued by Deutsche Atemwegsliga and Deutsche Gesellschaft fur Pneumologie und BeatmungsmedizinPneumologie2007615e1e40 German17436190
   PubMedGoogle Scholar
• ZhengJPKangJHuangSGEffect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled studyLancet200837196292013201818555912
   PubMed Web of Science ®Google Scholar
• PoolePChongJCatesCJMucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary diseaseCochrane Database Syst Rev20157Cd001287
   Google Scholar
• BeuscherNKietzmannMBienEChamperouxPInterference of myrtol standardized with inflammatory and allergic mediatorsArzneimittelforschung199848109859899825115
   PubMed Web of Science ®Google Scholar
• BeuscherNBienEElstnerEKietzmannMAmonUMyrtol standardized in treatment of sinusitis and bronchitis–Pharmacodynamics and pharmacokineticsZ Phytotherapie Abstractband19978910
   Google Scholar
• GrassmannJHippeliSDornischKRohnertUBeuscherNElstnerEFAntioxidant properties of essential oils. Possible explanations for their anti-inflammatory effectsArzneimittelforschung200050213513910719616
   PubMed Web of Science ®Google Scholar
• AppEMStellenwert der Mukusclearance für das Bronchialsystem – Pathophysiologie und therapeutische AnsätzeEntzündliche Erkrankungen des BronchialsystemsSpringer20002753
   Google Scholar
• BegrowFBockenholtCEhmenMWittigTVerspohlEJEffect of myrtol standardized and other substances on the respiratory tract: ciliary beat frequency and mucociliary clearance as parametersAdv Ther201229435035822477544
   PubMed Web of Science ®Google Scholar
• ChristophFKaulfersPMStahl-BiskupEIn vitro evaluation of the antibacterial activity of beta-triketones admixed to Melaleuca oilsPlanta Med200167876877111731927
   PubMed Web of Science ®Google Scholar
• LaiYDilidaerDChenBIn vitro studies of a distillate of rectified essential oils on sinonasal components of mucociliary clearanceAm J Rhinolo Allergy2014283244248
   Web of Science ®Google Scholar
• CaoLChenYZhaoYEffect of myrtol standardized on mucus hypersecretion and clearance of Pseudomonas aeruginosa in a rat model of chronic obstructive pulmonary diseaseArzneimittelforschung2011611268569222282955
   PubMed Web of Science ®Google Scholar
• UlmerWSchöttDChronisch-obstruktive Bronchitis. Wirkung von Gelomyrtol® forte in einer plazebokontrollierten DoppelblindstudieFortschr Med199110927547550 German1794831
   PubMedGoogle Scholar
• GillissenAWittigTEhmenMKrezdornHde MeyCA multi-centre, randomised, double-blind, placebo-controlled clinical trial on the efficacy and tolerability of GeloMyrtol® forte in acute bronchitisDrug Res (Stuttg)20136301192723447044
   PubMedGoogle Scholar
• MeisterRWittigTBeuscherNde MeyCEfficacy and tolerability of myrtol standardized in long-term treatment of chronic bronchitis. a double-blind, placebo-controlled study. Study Group InvestigatorsArzneimittelforschung199949435135810337455
   PubMed Web of Science ®Google Scholar
• MatthysHde MeyCCarlsCRysAGeibAWittigTEfficacy and tolerability of myrtol standardized in acute bronchitis. a multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial versus cefuroxime and ambroxolArzneimittelforschung200050870071110994153
   PubMed Web of Science ®Google Scholar
• WHOReport of an expert committee: Definition and diagnosis of pulmonary disease with special reference to chronic bronchitis and emphysemaWHO Techn Rep Ser196121319611419
   Google Scholar
• SantosSMarinASerra-BatllesJTreatment of patients with COPD and recurrent exacerbations: the role of infection and inflammationInt J Chron Obstruct Pulmon Dis20161151552527042040
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAHaganGAnsariZStockleyRAThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedererBGlaabTTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
   PubMed Web of Science ®Google Scholar
• MolyneauxPLMalliaPCoxMJOutgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2013188101224123123992479
   PubMed Web of Science ®Google Scholar
• VestboJLangePPrevention of COPD exacerbations: medications and other controversiesERJ Open Res20151100011201527730132
   PubMedGoogle Scholar
• SeemungalTHarper-OwenRBhowmikARespiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200116491618162311719299
   PubMed Web of Science ®Google Scholar
• StockleyRAO’BrienCPyeAHillSLRelationship of sputum color to nature and outpatient management of acute exacerbations of COPDChest200011761638164510858396
   PubMed Web of Science ®Google Scholar
• BafadhelMMcKennaSTerrySAcute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkersAm J Respir Crit Care Med2011184666267121680942
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMSeemungalTAThe role of bronchodilator treatment in the prevention of exacerbations of COPDEur Respir J20124061545155422835613
   PubMed Web of Science ®Google Scholar
• CalverleyPMRabeKFGoehringU-MKristiansenSFabbriLMMartinezFJRoflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trialsLancet2009374969168569419716960
   PubMed Web of Science ®Google Scholar
• PoolePBlackPNCatesCJMucolytic agents for chronic bronchitis or chronic obstructive pulmonary diseaseCochrane Database Syst Rev20128CD001287
   Google Scholar
• SocietyATStandards for the diagnosis and care of patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19951525 Pt 2S78S121
   Web of Science ®Google Scholar
• AnthonisenNManfredaJWarrenCHershfieldEHardingGNelsonNAntibiotic therapy in exacerbations of chronic obstructive pulmonary diseaseAnn Intern Med198710621962043492164
   PubMed Web of Science ®Google Scholar
• EffingTWKerstjensHAMonninkhofEMDefinitions of exacerbations: does it really matter in clinical trials on COPD?Chest2009136391892319736196
   PubMed Web of Science ®Google Scholar